Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression

Breast Cancer Research and Treatment

**Authors:** Charlotte Levin Tykjær Jørgensen¹, Carina Forsare¹, Pär-Ola Bendahl¹, Anna-Karin Falck², Mårten Fernö¹, Kristina Lövgren¹, Kristina Aaltonen³, Lisa Rydén⁴⁵

**Corresponding author:** Charlotte Levin Tykjær Jørgensen, PhD

Address: Department of Clinical Sciences, Lund, Division of Oncology and Pathology, Medicon Village, Building 404, Lund University, SE-22381 Lund, Sweden

Email: charlotte.levin_tykjaer_jorgensen@med.lu.se
**Supplementary Figure 1 a-k.** Kaplan-Meier survival curves showing distant recurrence-free interval (DRFi; years) in relation to epithelial-mesenchymal transition (EMT)-related marker and phenotype status in primary tumor and lymph node metastasis. E-cadherin (a-b), N-cadherin (c-d), twist (e-f), vimentin (g-h), EMT phenotype (i-j), EMT phenotype shift (k). P value from log rank test.

**Abbreviations:** EMT, epithelial-mesenchymal transition; PT, primary tumor; LNM, lymph node metastasis; DRFi, disease recurrence-free interval
PT

e) DRFI by twist expression

P = 0.01

f) DRFI by twist expression

P = 0.17

LNM

g) DRFI by vimentin expression

P = 0.57

h) DRFI by vimentin expression

P = 0.10

i) DRFI by EMT phenotype

P = 0.68

j) DRFI by EMT phenotype

P = 0.76
DRFi by EMT phenotype shift (PT-LNM)

$P = 0.85$